Shikiar Asset Management Inc. Reduces Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Shikiar Asset Management Inc. reduced its position in shares of OraSure Technologies, Inc. (NASDAQ:OSURGet Rating) by 24.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 15,400 shares of the medical instruments supplier’s stock after selling 5,000 shares during the quarter. Shikiar Asset Management Inc.’s holdings in OraSure Technologies were worth $104,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in OSUR. Lazard Asset Management LLC boosted its stake in shares of OraSure Technologies by 72.8% during the 4th quarter. Lazard Asset Management LLC now owns 7,737 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 3,260 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of OraSure Technologies during the 4th quarter worth about $92,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of OraSure Technologies by 61.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,871 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 4,522 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of OraSure Technologies by 31.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 13,969 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 3,362 shares during the last quarter. Finally, Aries Wealth Management acquired a new stake in shares of OraSure Technologies during the 4th quarter worth about $122,000. 97.00% of the stock is currently owned by institutional investors.

OSUR opened at $2.82 on Thursday. OraSure Technologies, Inc. has a 1 year low of $2.62 and a 1 year high of $13.57. The company’s 50 day simple moving average is $4.94 and its 200 day simple moving average is $7.01.

OraSure Technologies (NASDAQ:OSURGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). OraSure Technologies had a negative net margin of 19.25% and a negative return on equity of 12.15%. The business had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $60.17 million. During the same quarter in the previous year, the business posted $0.05 EPS. The company’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, equities research analysts anticipate that OraSure Technologies, Inc. will post -0.42 EPS for the current year.

Several equities research analysts have issued reports on the stock. Citigroup decreased their price target on shares of OraSure Technologies from $12.00 to $10.00 in a research note on Wednesday, May 11th. StockNews.com cut shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th. Finally, TheStreet cut shares of OraSure Technologies from a “c-” rating to a “d+” rating in a research report on Friday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $12.17.

OraSure Technologies Company Profile (Get Rating)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Articles

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSURGet Rating).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.